Patents by Inventor Michael Wayne Graham
Michael Wayne Graham has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210077959Abstract: A paddle mixer for evenly and efficiently mixing a volume of aggregate with minimal spillage is described. The paddle mixer includes a first portion, a second portion, a first paddle, and a second paddle. The paddle mixer may include a means for adjustably fixing the first portion to the second portion. The first paddle and the second paddle are arranged on the first portion and the second portion, respectively, such that the first paddle and the second paddle are perpendicular to each other, promoting mixing of the volume of aggregate with a whirlpool effect allowing mixing with minimal spillage. The first paddle and the second paddle may also be arranged perpendicular to each other by the means for adjustably fixing the first portion and the second portion.Type: ApplicationFiled: September 17, 2020Publication date: March 18, 2021Applicant: Honey Creek Innovations, LLCInventors: Michael Wayne Graham, Leonard Clyde Graham
-
Patent number: 10006048Abstract: The present invention relates generally to synthetic genes for modifying endogenous gene expression in a cell, tissue or organ of a transgenic organism, in particular a transgenic animal or plant. More particularly, the present invention provides novel synthetic genes and genetic constructs which are capable of repressing delaying or otherwise reducing the expression of an endogenous gene or a target gene in an organism when introduced thereto.Type: GrantFiled: June 30, 2016Date of Patent: June 26, 2018Assignee: COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATIONInventors: Michael Wayne Graham, Robert Norman Rice
-
Patent number: 9963698Abstract: The present invention relates generally to a method of modifying gene expression and to synthetic genes for modifying endogenous gene expression in a cell, tissue or organ of a transgenic organism, in particular a transgenic animal or plant. More particularly, the present invention utilizes recombinant DNA technology to post-transcriptionally modify or modulate the expression of a target gene in a cell, tissue organ or whole organism, thereby producing novel phenotypes. Novel synthetic genes and genetic constructs which are capable of repressing delaying or otherwise reducing the expression of an endogenous gene or target gene in an organism when introduced thereto are also provided.Type: GrantFiled: December 20, 2013Date of Patent: May 8, 2018Assignee: COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATIONInventors: Michael Wayne Graham, Robert Norman Rice, Peter Michael Waterhouse
-
Patent number: 9790502Abstract: This invention is directed to a RNA interference (RNAi) agent and the use of that RNAi agent to treat hepatitis B infection in individuals, as well as pharmaceutical compositions containing the RNAi agents of the invention. The RNAi agents, or constructs for expressing them are utilized to inhibit expression of at least one Hepatitis B virus (HBV) gene, where the agent comprises an effector sequence complementary to or substantially complementary to a predicted sequence transcribed from a target region. In some forms of the invention, the agent has more than one effector sequence. Multiple effectors may target the same region of an HBV gene, different (possibly overlapping) regions of the same gene and/or different HBV genes.Type: GrantFiled: July 11, 2016Date of Patent: October 17, 2017Assignee: BENITEC BIOPHARMA LIMITEDInventors: Michael Wayne Graham, Peter French, York YuanYuan Zhu, YiXiang Lu, TieJun Li, YunCheng Sun, XiaoJun Tang, Li Shan
-
Publication number: 20170114354Abstract: Methods and means are provided for reducing the phenotypic expression of a nucleic acid of interest in eucaryotic cells, particularly in plant cells, by introducing chimeric genes encoding sense and antisense RNA molecules directed towards the target nucleic acid, which are capable of forming a double stranded RNA region by base-pairing between the regions with sense and antisense nucleotide sequence or by introducing the RNA molecules themselves. Preferably, the RNA molecules comprises simultaneously both sense and antisense nucleotide sequence.Type: ApplicationFiled: September 8, 2016Publication date: April 27, 2017Applicant: Commonwealth Scientific & Industrial Research OrganisationInventors: Peter Michael Waterhouse, Ming Bo Wang, Michael Wayne Graham
-
Publication number: 20170002356Abstract: This invention is directed to a RNA interference (RNAi) agent and the use of that RNAi agent to treat hepatitis B infection in individuals, as well as pharmaceutical compositions containing the RNAi agents of the invention. The RNAi agents, or constructs for expressing them are utilised to inhibit expression of at least one Hepatitis B virus (HBV) gene, where the agent comprises an effector sequence complementary to or substantially complementary to a predicted sequence transcribed from a target region. In some forms of the invention, the agent has more than one effector sequence. Multiple effectors may target the same region of an HBV gene, different (possibly overlapping) regions of the same gene and/or different HBV genes.Type: ApplicationFiled: July 11, 2016Publication date: January 5, 2017Inventors: Michael Wayne Graham, Peter French, York YuanYuan Zhu, YiXiang Lu, TieJun Li, YunCheng Sun, XiaoJun Tang, Li Shan
-
Publication number: 20170002379Abstract: The present invention relates generally to synthetic genes for modifying endogenous gene expression in a cell, tissue or organ of a transgenic organism, in particular a transgenic animal or plant. More particularly, the present invention provides novel synthetic genes and genetic constructs which are capable of repressing delaying or otherwise reducing the expression of an endogenous gene or a target gene in an organism when introduced thereto.Type: ApplicationFiled: June 30, 2016Publication date: January 5, 2017Inventors: Michael Wayne Graham, Robert Norman Rice
-
Patent number: 9518260Abstract: The disclosure relates to an RNA interference (RNAi) agent and the use of that RNAi agent to treat chronic pain in individuals, as well as pharmaceutical compositions containing the RNAi agents of the invention. The DNA-directed RNA interference (ddRNAi) agent for inhibiting expression of one or more target sequences in a pain associated gene comprises, one or more effector sequence sequences and effector complement sequences of at least 17 nucleotides in length, wherein the effector sequence is substantially complementary to the predicted transcript of a target sequence within a pain associated gene.Type: GrantFiled: February 28, 2013Date of Patent: December 13, 2016Assignee: Benitec Biopharma LimitedInventors: Peter William French, Michael Wayne Graham
-
Patent number: 9441239Abstract: Methods and means are provided for reducing the phenotypic expression of a nucleic acid of interest in eucaryotic cells, particularly in plant cells, by introducing chimeric genes encoding sense and antisense RNA molecules directed towards the target nucleic acid, which are capable of forming a double stranded RNA region by base-pairing between the regions with sense and antisense nucleotide sequence or by introducing the RNA molecules themselves. Preferably, the RNA molecules comprises simultaneously both sense and antisense nucleotide sequence.Type: GrantFiled: March 1, 2006Date of Patent: September 13, 2016Assignee: Commonwealth Scientific & Industrial Research OrganisationInventors: Peter Michael Waterhouse, Ming-Bo Wang, Michael Wayne Graham
-
Patent number: 9410154Abstract: RNA interference (RNAi) agents and the use of the RNAi agents for treating hepatitis B infection in individuals, as well as pharmaceutical compositions containing the RNAi agents are provided. The RNAi agents, or constructs for expressing them are utilized to inhibit expression of at least one Hepatitis B virus (HBV) gene, wherein each agent comprises an effector sequence complementary to or substantially complementary to a predicted sequence transcribed from a target region. In some embodiments of the present invention, the agents have more than one effector sequence; wherein the multiple effectors may target the same region of an HBV gene, different (possibly overlapping) regions of the same gene and/or different HBV genes.Type: GrantFiled: June 5, 2015Date of Patent: August 9, 2016Assignee: BENITEC BIOPHARMA LIMITEDInventors: Michael Wayne Graham, Peter French, York YuanYuan Zhu, YiXiang Lu, TieJun Li, YunCheng Sun, XiaoJun Tang, Li Shan
-
Publication number: 20150344885Abstract: RNA interference (RNAi) agents and the use of the RNAi agents for treating hepatitis B infection in individuals, as well as pharmaceutical compositions containing the RNAi agents are provided. The RNAi agents, or constructs for expressing them are utilized to inhibit expression of at least one Hepatitis B virus (HBV) gene, wherein each agent comprises an effector sequence complementary to or substantially complementary to a predicted sequence transcribed from a target region. In some embodiments of the present invention, the agents have more than one effector sequence; wherein the multiple effectors may target the same region of an HBV gene, different (possibly overlapping) regions of the same gene and/or different HBV genes.Type: ApplicationFiled: June 5, 2015Publication date: December 3, 2015Inventors: Michael Wayne Graham, Peter French, York YuanYuan Zhu, YiXiang Lu, TieJun Li, YunCheng Sun, XiaoJun Tang, Li Shan
-
Publication number: 20150322458Abstract: The present invention relates generally to synthetic genes for modifying endogenous gene expression in a cell, tissue or organ of a transgenic organism, in particular a transgenic animal or plant. More particularly, the present invention provides novel synthetic genes and genetic constructs which are capable of repressing delaying or otherwise reducing the expression of an endogenous gene or a target gene in an organism when introduced thereto.Type: ApplicationFiled: April 16, 2015Publication date: November 12, 2015Inventors: Michael Wayne Graham, Robert Norman Rice
-
Patent number: 9080174Abstract: RNA interference (RNAi) agents and the use of the RNAi agents for treating hepatitis B infection in individuals, as well as pharmaceutical compositions containing the RNAi agents are provided. The RNAi agents, or constructs for expressing them are utilized to inhibit expression of at least one Hepatitis B virus (HBV) gene, wherein each agent comprises an effector sequence complementary to or substantially complementary to a predicted sequence transcribed from a target region. In some embodiments of the present invention, the agents have more than one effector sequence; wherein the multiple effectors may target the same region of an HBV gene, different (possibly overlapping) regions of the same gene and/or different HBV genes.Type: GrantFiled: October 27, 2011Date of Patent: July 14, 2015Assignee: BENITEC BIOPHARMA LIMITEDInventors: Michael Wayne Graham, Peter French, York YuanYuan Zhu, Yixiang Lu, TieJun Li, Yuncheng Sun, XiaoJun Tang, Li Shan
-
Patent number: 9029527Abstract: The present invention relates generally to synthetic genes for modifying endogenous gene expression in a cell, tissue or organ of a transgenic organism, in particular a transgenic animal or plant. More particularly, the present invention provides novel synthetic genes and genetic constructs which are capable of repressing delaying or otherwise reducing the expression of an endogenous gene or a target gene in an organism when introduced thereto.Type: GrantFiled: April 19, 2013Date of Patent: May 12, 2015Assignee: Commonwealth Scientific and Industrial Research OrganisationInventors: Michael Wayne Graham, Robert Norman Rice
-
Publication number: 20150045411Abstract: The disclosure relates to an RNA interference (RNAi) agent and the use of that RNAi agent to treat chronic pain in individuals, as well as pharmaceutical compositions containing the RNAi agents of the invention. The DNA-directed RNA interference (ddRNAi) agent for inhibiting expression of one or more target sequences in a pain associated gene comprises, one or more effector sequence sequences and effector complement sequences of at least 17 nucleotides in length, wherein the effector sequence is substantially complementary to the predicted transcript of a target sequence within a pain associated gene.Type: ApplicationFiled: February 28, 2013Publication date: February 12, 2015Inventors: Peter William French, Michael Wayne Graham
-
Publication number: 20140193856Abstract: The present invention relates generally to a method of modifying gene expression and to synthetic genes for modifying endogenous gene expression in a cell, tissue or organ of a transgenic organism, in particular a transgenic animal or plant. More particularly, the present invention utilizes recombinant DNA technology to post-transcriptionally modify or modulate the expression of a target gene in a cell, tissue organ or whole organism, thereby producing novel phenotypes. Novel synthetic genes and genetic constructs which are capable of repressing delaying or otherwise reducing the expression of an endogenous gene or target gene in an organism when introduced thereto are also provided.Type: ApplicationFiled: December 20, 2013Publication date: July 10, 2014Applicant: Commonwealth Scientific and Industrial Research OrganisationInventors: Michael Wayne Graham, Robert Norman Rice, Peter Michael Waterhouse
-
Patent number: 8598332Abstract: Methods and means are provided for reducing the phenotypic expression of a nucleic acid of interest in eucaryotic cells, particularly in plant cells, by introducing chimeric genes encoding sense and antisense RNA molecules directed towards the target nucleic acid, which are capable of forming a double stranded RNA region by base-pairing between the regions with sense and antisense nucleotide sequence or by introducing the RNA molecules themselves. Preferably, the RNA molecules comprises simultaneously both sense and antisense nucleotide sequence.Type: GrantFiled: April 7, 1999Date of Patent: December 3, 2013Assignee: Bayer CropScience N.V.Inventors: Peter Michael Waterhouse, Ming-Bo Wang, Michael Wayne Graham, Neil A. Smith
-
Publication number: 20130298264Abstract: The present invention relates generally to synthetic genes for modifying endogenous gene expression in a cell, tissue or organ of a transgenic organism, in particular a transgenic animal or plant. More particularly, the present invention provides novel synthetic genes and genetic constructs which are capable of repressing delaying or otherwise reducing the expression of an endogenous gene or a target gene in an organism when introduced thereto.Type: ApplicationFiled: April 19, 2013Publication date: November 7, 2013Applicant: Commonwealth Scientific and Industrial Research OrganisationInventors: Michael Wayne Graham, Robert Norman Rice
-
Publication number: 20130296401Abstract: RNA interference (RNAi) agents and the use of the RNAi agents for treating hepatitis B infection in individuals, as well as pharmaceutical compositions containing the RNAi agents are provided. The RNAi agents, or constructs for expressing them are utilized to inhibit expression of at least one Hepatitis B virus (HBV) gene, wherein each agent comprises an effector sequence complementary to or substantially complementary to a predicted sequence transcribed from a target region. In some embodiments of the present invention, the agents have more than one effector sequence; wherein the multiple effectors may target the same region of an HBV gene, different (possibly overlapping) regions of the same gene and/or different HBV genes.Type: ApplicationFiled: October 27, 2011Publication date: November 7, 2013Applicants: BIOMICS BIOTECHNOLOGIES CO., LTD, BENITEC BIOPHARMA LIMITEDInventors: Michael Wayne Graham, Peter French, York YuanYuan Zhu, Lu YiXiang, Li TieJun, Sun YunCheng, Tang XiaoJun, Shan Li
-
Patent number: 8431547Abstract: The present invention relates generally to synthetic genes for modifying endogenous gene expression in a cell, tissue or organ of a transgenic organism, in particular a transgenic animal or plant. More particularly, the present invention provides novel synthetic genes and genetic constructs which are capable of repressing delaying or otherwise reducing the expression of an endogenous gene or a target gene in an organism when introduced thereto.Type: GrantFiled: November 7, 2011Date of Patent: April 30, 2013Assignee: Commonwealth Scientific and Industrial Research OrganisationInventors: Michael Wayne Graham, Robert Norman Rice